読み込み中
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
前日終値
$0.6437
+$0.0335 · +5.49%
時間外
$0.668
+$0.0243 · +3.78%
10月12日 19:12 ET
日中の時刻はETです。市場データは遅延する場合があります。
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
日中レンジ
現在 $0.6437
52週レンジ
現在 $0.6437
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
41
まちまち
リスク
69
高リスク
モメンタム
25
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
日中レンジ
現在 $0.6437
52週レンジ
現在 $0.6437
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|
| 研究開発 | 1029.26万 USD | 1867.63万 USD | 2170.83万 USD | 1638.72万 USD |
| 販売・一般管理 | 1220.27万 USD | 648.45万 USD | 326.55万 USD | 381.96万 USD |
| 営業費用 | 2249.53万 USD | 2516.07万 USD | 2497.38万 USD | 2020.68万 USD |
| 受取利息 | 28.77万 USD | 22.23万 USD | 35.27万 USD | 2.7万 USD |
| 支払利息 | 2.03万 USD | −1.87万 USD | 4.36万 USD | 1.62万 USD |
| 減価償却費と償却費 | — | 2516.07万 USD | 2497.38万 USD | 2020.68万 USD |
| 営業利益 | −2249.53万 USD | −2516.07万 USD | −2497.38万 USD | −2020.68万 USD |
| 純利益 | −2222.79万 USD | −2728.53万 USD | −2474.46万 USD | −2015.94万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$21.00
上昇余地（3162.39%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI43.68万0.00%2.3兆 USD0.03%$381.57-0.10%
Vanguard Extended Market ETFVXF16.12万0.00%954億 USD0.05%$233.52-0.63%
iShares Micro-Cap ETFIWC2.21万0.00%13.17億 USD0.60%$181.66-0.73%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM1万0.01%1.16億 USD0.73%$15.8484-0.58%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
